Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
doesn't that hypothesis rest upon the assumption that SCRC won't be engaging an any more toxic financing? what evidence do we have, what track record to follow, that there won't be more toxic financing going on?
i understand very well how taking the easy toxic money with the best of intentions to pay it back spirals out of control. sometimes taking the money is to keep operations going, other times its for the officers to pay their salaries and travel. other times a combination of dozens of business factors.
need a big update soon on Hong Kong, China and any other deals going on.
ps- does anyone have a comparable company in terms of the level of toxic financing received that has pulled out of it intact? and not only pulled out of it, has thrived?
Nice summation Bsav. We should remember to that in addition to the HK and China markets, Scrips is also probably exploring additional foreign markets to enter into. With their JV partners, Scrips has the ability to prepare to enter multiple foreign markets simultaneously. The JV partners most likely shoulder the majority of burden of market entry preparation (product approval, distribution set up, etc) and take a cut of sales/profits. Win-win-win situation: scrips wins, jv partners win, shareholders win.
Again, the power of teaming up with others instead of trying to do it all yourself.
I still wonder about US sales? I understand needing joint venture partners to penetrate foreign markets, but what about US efforts? Are those on-going? Any timetable when there will be an official US launch? I would think that with the JV partners managing the foreign distribution efforts to a degree, Scrips would be freed to launch US sales?
Agree Flyers. The notes are the elephant in the room. No question.
But, if Scrips keeps showing positive corporate momentum, hopefully there will be sufficient market support to absorb the note selling to a point that we have some stability and a path upwards.
Hold the line and stay the course!
100% agree BSAV. If you guys want some DD, just check out the Scrips China investor packet:
http://scripsamerica.com/wp-content/uploads/2014/02/ScripsAmerica-China-Package-2014-Web.pdf
Literal road map of their plan to penetrate the China market. Talks about the market, the product platform, their marketing strategies, everything. Is worth the read.
Once the first P.O. is placed, I imagine we will see a nice SP increase and some happy shareholders who bought in at these low prices
Drepark, again, that "DD" lacks in a couple areas. But, lets review:
Scrips has a JV agreement with Global Pharma. RapiMed is approved for sale in Hong Kong.
Scrips says purchase order committments are being solicited for right now.
The "knock" of global pharma is that it is a newly formed corporation. So what? I say what matters are the principals behind global pharma. Per their website, they are a collection pharmaceutical professionals, venture capitalists and investment bankers with broad international experience. The group has pooled their talents into a licensing, marketing and distribution firm for OTC and medical products because they believe there is profit to be made.
What I am trying to say is that the birthdate of a company has NOTHING to do with the experience of the principals behind the company. Businessmen with decades of experience in their respective fields open a new company and that company carries with it all the experience that the businessman brings.
So, give Global Pharma and Scrips a shot. They achieved RapiMed registration approval in Hong Kong, which some on this board doubted. Next, they are going for sales, which, again, some on this board will doubt. In my opinion, they will be proved wrong.
Once first purchase orders are received, what will the doubters say next?
SCRC, at this point, deserves some more time before negative judgements are heaped upon them. They just achieved approval to sell RapiMed in HK for gods sakes. Give em a shot!
That a company called Global Pharma Hub has the licensing and distribution rights to RapiMed. Most likely, in my opinion, Global Pharma has partnered with a Hong Kong domiciled importer so RapiMed can be imported. I imagine Forbes, the original China player in this mix, is associated with or arranged the importer.
I found Global Pharma's website: www.globalpharmahub.com
Appears they specialize in taking medicines and medical products and packaging them for licensing, marketing and distribution into new foreign markets. The jury is out on their abilities, but Scrips signed with them so there must be confidence in performance capabilities.
We should know shortly regarding RapiMed registration approval. If it is approved, that is major, monumental news and the door officially opening to the China market.
Extensive Overview of the China venture on Scrips Website. Really breaks down the plan of entering the market and is quite detailed. Worth the read!!!!
Downloadable on this page:
http://scripsamerica.com/rapimed-china/
Or directly download here:
http://scripsamerica.com/wp-content/uploads/2014/02/ScripsAmerica-China-Package-2014-Web.pdf
NEW INVESTOR PACKET ON SCRIPS WEBSITE!!!!
http://scripsamerica.com/wp-content/uploads/2014/02/ScripsAmerica-China-Package-2014-Web.pdf
Looks very well done and put together.
NEWS ANALYSIS:
Global Pharma appears to be the facilitator between Scrips and NYJJ. Global Pharma holds the license and thus is actively pursuing opportunities to sell RapiMed in Hong Kong.
NYJJ must be a HK domiciled corporation that is able to market and solicit orders.
While the release may have been a little clumsy, it is good news. It shows forward movement. This shouldn't be looked upon negatively in any way.
I am sure we will hear more about the elements of this deal in the coming days and weeks.
Hong Kong drug market:
Hong Kong has just over 7 million people and they are extremely health conscious consumers. They are trendy, cutting edge consumers who highly value "name brand" goods. Hong Kong is the pearl of Asia, has a booming economy and 3% unemployment. The people are willing to spend their money on their health!
Fun Facts:
- Hong Kong healthcare market growing at an average range of 6-7%
- Hong Kong is a major re-export hub for China! For Scrips, Hong Kong is literally the launching point into the mainland!
- The US and Australia are the leading importers of vitamin and health supplements.
- Hong Kong pharma market forecasted to reach $1.5 Billion by 2019
- Robust pharmacy and health retail market with leaders "Watsons" and "Manning"
- Aging population drives the healthcare market. RapiMeds is an ideal delivery mechanism for elderly patients due to quick dissolve, waterless technology. RapiMed can be applied to high demand formulations for the elderly that include joint support, bone enhancement, anti-ageing, heart health.
- Hong Kong's healthcare system is so efficient and attractive that millions of mainland Chinese flock to Hong Kong every year to have their babies! This means a steadily growing pediatric market.
HONG KONG IS THE PERFECT MARKET FOR SCRIPS TO ENTER FIRST AND SELL RAPIMED. SCRIPS CAN BUILD BRAND RECOGNITION IN A SAVVY CONSUMER MARKET, WHICH WILL PROVIDE SCRIPS A SOLID FOUNDATION FROM WHICH TO ENTER MAINLAND CHINA. HONG KONG RESIDENTS KNOW AND TRUST AMERICAN BRANDS.
IT IS LOGICAL TO ASSUME THAT THE SAME DISTRIBUTION PARTNERS IN HONG KONG WILL WANT TO MARKET AND CARRY RAPIMED IN CHINA, PROVIDING SMOOTH MARKET PENETRATION AND LOWER OVERALL ENTRY AND MARKETING COSTS.
Sources:
http://www.mitc.com/trade/documents/BiotechnologyandMedicalProductsIndustriesReport-ChinaandHK.pdf
http://www.thepharmaletter.com/article/bmi-ups-forecast-for-hong-kong-pharma-market-to-1-53-billion-in-2019
http://www.euromonitor.com/consumer-health-in-hong-kong-china/report
http://www.nytimes.com/2012/02/23/world/asia/mainland-chinese-flock-to-hong-kong-to-have-babies.html?pagewanted=all&_r=0
HIGHEST DEMAND CATEGORIES FOR PEDIATRIC VITAMINS:
· Vitamin A promotes normal growth and development; tissue and bone repair; and healthy skin, eyes, and immune responses. Good sources include milk, cheese, eggs, and yellow-to-orange vegetables like carrots, yams, and squash.
· Vitamin Bs. The family of B vitamins -- B2, B3, B6, and B12 -- aid metabolism, energy production, and healthy circulatory and nervous systems. Good sources include meat, chicken, fish, nuts, eggs, milk, cheese, beans, and soybeans.
· Vitamin C promotes healthy muscles, connective tissue, and skin. Good sources include citrus fruit, strawberries, kiwi, tomatoes, and green vegetables like broccoli.
· Vitamin D promotes bone and tooth formation and helps the body absorb calcium. Good sources include milk and other fortified dairy products, egg yolks, and fish oil. The best source of vitamin D doesn't come from the diet -- it's sunlight.
· Calcium helps build strong bones as a child grows. Good sources include milk, cheese, yogurt, tofu, and calcium-fortified orange juice.
· Iron builds muscle and is essential to healthy red blood cells. Iron deficiency is a risk in adolescence, especially for girls once they begin to menstruate. Good sources include beef and other red meats, turkey, pork, spinach, beans, and prunes.
Scrips can provide efficient, water free delivery of vitamins in RapiMed format to China OTC pediatric market. The demand is clearly proven in China for American made medicines.
I like the how Scrips is talking about RapiMed product diversification. Acetaminophen is obviously a great, all around product for reducing fever and pain reduction, but being able to enter the nutraceutical, sexual health, vitamin and other generic OTC meds categories is vital for Scrips market expansion in Asia and beyond.
Scrips, to me, appears in "brand building" mode for China. By addressing multiple health categories through diverse RapiMed applications, Scrips is paving the foundation for a long term market effort.
NEW RAPIMED CHINA PAGE ON WEBSITE.
http://scripsamerica.com/rapimed-china/
I like the look of things. I was pessimistic for a while about Scrips pulling the China venture off, but it appears they are getting very close.
The China venture is the game changer for the Company.
I gotta admit, I have never seen such positivity in the face of such sheer negative evidence. I guess when you are in as deep as you guys are, you have no choice but to be positive and hope there is light at the end of the tunnel.
Massive dilution and toxic financing? = Great buying opportunity
Float growing by the day? = Great buying opportunity
Promotional shares being handed out like Halloween Candy? = Great buying opportunity
LOL. Shock and Awe, the heavy hittin P&D team.
I mean, you have to give it to them. They did a near flawless P&D. Textbook stuff.
the rabbit out the hat will be if scrips can secure non-toxic financing. any more toxic convertible notes and we are looking at micro penny land. Plus, I wonder how many shares are out there in the hands of the conv note holders? The holders don't care about the company, just about selling, so no matter what there is still stock to go through. Whether its a small hill or a mountain, I don't know.
IFFFFFF SCRC can secure non-toxic financing, or have some angel put up the money on very easy terms, then there is light at the end of tunnel. RapiMed production and distribution is their only hope to really pull out of this.
The market for RapiMed is there, no doubt.
Where can we find Celtics to thank him for all his "great DD"? The rest of the pumpers have grown wings and flew away. Forgot that certain species of roaches can fly :)
$3.5 Million Panel Order Just Came In!!
http://finance.yahoo.com/news/first-power-light-receives-3-130248000.html
This stock is steal at these prices. Post acquisition of FPL, LLC it looks like VOLT will show around $10M+ in sales with great earnings.
$.20 is absurdly cheap. I see this thing at a $1 by years end
Shock and Awe principals are, in my opinion, the noteholders who simply do toxic financing through another front company, then pump through Shock and Awe, where they can legitimately say that Shock and Awe isn't an IR firm.
Simple strategy, really, that is has been done by a wide range of groups for some time across OTCBB land.
I agree. With the news out and the pending acquisition, there is no reason to not consider taking a long position in this stock in my opinion.
There is obvious support behind VOLT
Art, well put on point number 1, which is solid truth.
Yea, there has been some pumpin rhetoric for sure. Usually identified by promotional style comments lacking any substance. Anyways, pumping talk in my opinion doesn't help.
But, lets see what happens between now and end of year. The company will or won't survive its toxic financing and turn things around with US RapiMed distribution, strong revenues in the retail pharmacy distribution venture, and some exciting developments from China.
Flyers, thank you for clarification and your homework. Hate to sound rhetorical, but this is very bad.
Seems like some sort of convertible note ponzi death spiral. Offer new convertible notes to attempt to pay off old note holders before the note maturity and share conversion.
Scrips needs a major play, some serious financing in the form of an acquisition or something along those lines.
You said. This is toxic financing at its worst. Anyone trying to spin millions of of shares coming free as a positive event to pick up cheap shares is delusional or, at worst, one of the financiers themselves trolling these boards encouraging buying while they are selling. You know who you are.
This is going to bottom out around 15-17 cents, which is what I believe the conversion price is. So, more pain ahead but once the virus of the financiers has sold itself through, the Company can have a clean slate
I am not certain, but I believe their last Q stated that their national distribution of RapiMeds could not commence until their received further financing. So,in all likelihood manufacturing, let alone distribution, won't be happening in September.
The stock drop was due to convertible note holders exercising the conversion option due to SCRC inability to pay off the notes before note maturity. The note holders sold heavy, thus the drop.
The stock seems to have leveled out for the time being. Note holders may have exhausted majority of their conversion shares.
I have a feeling there are quite a few investors on the sidelines right now watching for a bit to see what happens over September. They saw the stock reach $1 a couple months back on incredible volume. If the note holders are indeed dried out, we could see another run buttressed by some big news.
Lol. I know that some of the fluffy rhetoric around here can feed suspicions of pumpers, especially considering we are seeing the end results of a tsunami of convertible note holders selling. Makes you think the ones telling you to buy now are the same ones selling. Tried and true strategy of pumpers and toxic financiers.
But, in my opinion, between now and the end of the year, we will know if SCRC is the real deal or not. RapiMeds will either be launched in the US or they wont within this time. The China venture will or won't show substantive movement within this time. And Scrips U.S. retail pharmacy distribution will have continued to produce strong revenues or not.
All stocks are an educated gamble to a degree. So, look at the pieces on the table, read their filings, and if you come to the conclusion that SCRC has a positive future, then now would be the time to buy at these low prices.
Excellent China DD article for RapiMeds:
China's population is aging rapidly, with more elderly and retirement age individuals outpacing other age demographic categories, and their govt is considering loosening the one child policy to help balance out population. RapiMeds is the perfect medicinal delivery method for the young and old.
***number of elderly in China is expected to rise from 194 million in 2012 to 300 million by 2025*****
http://www.stratfor.com/analysis/china-unprecedented-demographic-problem-takes-shape
We should mix reality with optimism.
Reality:
- RapiMeds is not launching in September unless they secure financing
- To manufacture and distribute orders takes 60 days or so
- They haven't secured the financing and even if they did, there wouldn't be distribution, and thus sales, till late October/Nov
- There are note holders selling hard, which is causing a heavy drop in the sp. This is to be expected
- SCRC issued more notes the last quarter
- There is a good possibility that some of the those noteholders are on this board rallying people to buy.So, read between the lines with some individuals
Optimism:
- RapiMed is a one of kind product that can be diversified into multiple product channels: vitamins, sleep aid, allergy, nutraceutical, etc
- RapiMed can literally become a household name over the next year
- SCRC is lining up a China RapiMed distribution venture that has potential to produce record breaking sales
- SCRC China venture will inevitably put international eyes on the stock and should result in buying from groups on the China end that are involved in the RapiMed deal
- SCRC has a US retail pharmacy distribution deal that is kicking into gear and will produce healthy, reliable sales
- The note holders have been selling hard and probably close to being out of shares and close to their "basement" conversion price
- Hopefully any other financing the company takes in is debt financing and not conv notes. At this point, better to deal with debt burden than more convertibles
So, like a pilot would say, please stay seated and buckle your safety belt. There will be conv note selling turbulence, but we should be out of it soon and there will be clear skies ahead!
100% agree. Let them get out now while the price is low. Don't want to have to buy through them at higher levels. Between $.30 and $.20 they will burn off their shares and after that there will be little resistance and the stock will climb based upon revenues, future potentials and committed shareholder base.
I agree Steltz. Listen, the conv note guys are selling through and soon they will be done. We don't want them here anyways. All I am trying to say is that of course the stock will have some turbulence if there are some note holders selling. But, I think they are nearly through with their shares, so the downward pressure will let up soon.
The trading activity is solely due to the noteholders, not indicative of some fundamental or underlying company flaws. Let them sell off now anyways because with the upcoming ventures, the stock will rise.
The question is whether there is enough buying power to take out the convertible loan groups who are pounding this stock like a drunk college co-ed on Saturday night.
I got in at the 40's and mid 30's. Some big money groups have got to come in to clean out these guys, or, Scrips needs to have some major news coming to rally attention to the stock and create adequate buying momentum to clear out the conv loaners. They aren't in it for the long haul and are just seeking to get out now while they spread around more toxic financing.
Bring on the big news!!!!!
No need to attack. If you consider posting the exact 10Q as "tainted DD", just.....wow.
In my opinion, the note-holders are the number one concern, because their only concern is selling. Besides the note-holders, SCRC has some positive footing with their new independent pharmacy distribution operation and the potential China deal. US RapiMed sales, when/if they take off dependent upon securing financing, should produce significant sales and great PR. So, there are positive factors to grab onto. No need to overreact over a less than stellar Q.
I also believe some of the noteholders have been posting on this board, attacking people who raise legitimate issues regarding the 10Q. Only logical answer.
Yes. This is not a positive filing. Read carefully. They said they can't begin RapiMed production and distribution without further financing. They are already up to their necks in toxic convertible note financing. Essentially, there is no RapiMed unless they get more money.
Lets just hope that there are some Chinese partners willing to put up PO money and wait for the 60-90 days till product production and delivery for their orders.
Well, the $1 price was attributed by many across the numerous web boards to be a pump and dump run. Stock went up on crazy hype, feeding frenzy, then the dump. In my humble opinion, the reason the stock is struggling at the $.30's range has to do with the convertible notes the company issued out over the years. The notes were converted to restricted stock and now they are free and the note holders are selling hard. They would have got their stock at a significant discount at time of note execution, so, any stock sales above their discounted base conversion price is profit.
In fact, I wouldn't be surprised if some of the hypesters across the web are actually the note holders themselves trying to rally investors while they sell. Lol. I have seen it happen numerous times before.
So, SCRC has potential, big potential, with RapiMed sales both in the US and China as well as their retail pharmacy distribution operations which are kicking back into gear.
I look forward to the upcoming 10Q which hopefully shed some light
I agree. Examine First Power and Light, LLC website: http://www.firstpowerandlight.com/
This is the company being acquired by VOLT. FPL, LLC has completed over 400 solar installations for Federal, Commercial and Residential clients. They are well known across the PA and NJ solar markets. This is a good company and this is what is going to bring solid momentum to this stock.
In my opinion, price is low compared to what it will be post-acquisition.
The stock is showing some very attractive gains. With the pending acquisition of First Power and Light, LLC, which is a solid solar installer with substantial government contracts with HUD and significant residential and commercial solar installs all across PA and NJ, we should see some nice momentum soon. Go review the past press releases and website. Further, if you can, get your hands on one of their previous investor reports they put out about two months back. It was on their website to download.
VOLT is a quiet player right now but the gains will be on soon.
You got it Jerrymike. A stock price decreasing is never good no matter how you spin. We want stock prices going up. lol.
Now, if it is noteholders converting into discounted stock, then at least we know what his happening. Next question is what is the wall of stock we are facing? This plays into my trading strategy.
If I know there is a large block of discounted stock being converted by noteholders who may have a "sell off" mentality, then that means I am not going to continue to buy, buy, buy knowing that a huge selloff is taking place. I would like to determine what the conversion price was for them. For example, if SCRC got $150K convertible note financing with conversion rights at $.20 a share, then that means the note holder will be sitting on 750,000 shares. So, selling anything above $.20 is profit to them and $.20 is their basement. If it is noteholders slamming the stock,expect the selloff to go till they reach their basement.
Any help deciphering the situation would be greatly appreciated. If I am wrong about the noteholder situation, then I am pre-apologizing right now! I like this little company and believe it can grow into a big company and that is why I am here.
Have a good weekend guys.
Relax. I am not doom and gloom and I hold positions in the stock. If you get mad at me for an honest critique, then lord help this board and this stock.
I am not saying this is some insurmountable problem. But, it sure doesn't hurt to isolate down the sources of selling centers. By doing so, we can at least know and identify what is happening and formulate proper trading strategies.
If you get mad at me for that, thats your problem
Im telling you, it is the note holders. There must be note holders whose paper is now coming free because SCRC couldn't pay it all the principal and interest back.
The upcoming filing will tell all. But, you heard it here, these are restricted shares held by conv note holders that are coming free.
What is the status with the convertible notes? I have seen the press releases saying they are repaying parts of the notes, but I would imagine the sudden selling onslaught is for remaining unpaid portions of outstanding convertible notes are now coming free.
I am just not sure who holds the notes. Could be some predatory groups that take advantage of capital starved pubcos. Then, once the paper is free, they sell hard, considering they probably bought the notes at a very low stock conversion ratio.
What Scrips news is some solid news and start showing some revs from the US retail pharmacy deal. Also, the Hong Kong due-dili trip kick off.